Investor Presentaiton

Oncology Opdivo Opdualag TIGIT Bispecific DGK Inhibitor AR LDD Effective & tolerable treatment options needed in metastatic castrate resistant prostate cancer (mCRPC) High unmet need remains in prostate cancer: . Expected U.S. mortality is -35K¹ men in 2023 5-year OS¹ decreases from >97% to -32.5% in the localized vs metastatic setting Current SOC - NHT2 • AR is a key driver of prostate cancer and AR-targeted therapies remain current SoC • • Traditional AR antagonists (e.g., enzalutamide) inhibit AR in a reversible manner This AR inhibition is overcome by upregulation of wildtype (WT) or mutation of AR in cancer cells, leading to resistance: - AR WT amplification (-50%)³ AR LDD AR LDD induces irreversible AR degradation in a catalytic manner leading to deeper, more potent AR inhibition • Potentially paradigm-shifting MoA overcomes resistance mechanisms to NHT including AR WT amplification and mutations Preclinical models demonstrated activity in both settings Potential to improve efficacy, safety, & tolerability in the post-NHT setting • - AR mutations (~15-20%)³ Post-NHT progression, limited options for patients (e.g., chemo) Ill Bristol Myers Squibb™ 1. SEER 2023; 2. NHT: e.g., enzalutamide and abiraterone; 3. Robinson, et al., 2015, Cell 161:1215; Abida et al., 2019, PNAS 116:11428. Not for Product Promotional Use 104

View entire presentation